Bimal Shah, MD
Internal Medicine · Augusta, GANPI 1043319890
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,870 of the $7,362 with a category attached, or 79.7%. 33 manufacturers reported payments, led by Abbott at 25.9% of the total. Reporting peaked in 2019 at $2,904 and has fallen 80.0% since, to $581 in 2025. Among internal medicine clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 261 payments — averaging $28.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Johnson & Johnson$722
- AstraZeneca$605
- Novartis$594
- E.r. Squibb & Sons, L.L.C.$584
- Merck$481
- plus $2K from 27 others
What the payments were for
- Travel & lodging$1,24317%
- Food & beverage$5,87080%
- Education$2493%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 12 | $1,910 |
| Johnson & Johnson | 39 | $722 |
| AstraZeneca | 27 | $605 |
| Novartis | 24 | $594 |
| E.r. Squibb & Sons, L.L.C. | 20 | $584 |
| Merck | 21 | $481 |
| Boehringer Ingelheim | 20 | $401 |
| Pfizer | 19 | $397 |
| Esperion Therapeutics, Inc. | 13 | $293 |
| Boston Scientific | 8 | $268 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $215 |
| Amgen | 10 | $184 |
| Biotronik Inc. | 4 | $96 |
| Medicomp Inc | 3 | $78 |
| Alnylam Pharmaceuticals Inc. | 3 | $47 |
| Regeneron Healthcare Solutions, Inc. | 3 | $45 |
| Bayer | 3 | $43 |
| Astellas Pharma US Inc | 3 | $43 |
| Lexicon Pharmaceuticals, Inc. | 2 | $36 |
| Abiomed | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Davol Inc. | 1 | $31 |
| Amarin Pharma, Inc. | 2 | $27 |
| Actelion Pharmaceuticals US, Inc. | 1 | $26 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Novo Nordisk | 1 | $25 |
| Medtronic | 1 | $21 |
| Altathera Pharmaceuticals LLC | 1 | $19 |
| GSK | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Coala Life Inc | 1 | $16 |
| Cardiva Medical, Inc. | 1 | $14 |
| Infobionic, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xience V coronary stent system$1,013
- Omnilink Elite vascular stent system$673
- GENERAL - STENTS$125
- ENTRESTO$125
- ELIQUIS$125
- XARELTO$112
- CAMZYOS$100
How this compares
$7,362 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 528 | $459,108 |
| EntrestoSacubitril/Valsartan | 246 | $282,740 |
| XareltoRivaroxaban | 158 | $150,786 |
| JardianceEmpagliflozin | 49 | $53,270 |
| Repatha SureclickEvolocumab | 62 | $48,149 |
| FarxigaDapagliflozin Propanediol | 32 | $45,994 |
| BrilintaTicagrelor | 29 | $22,438 |
| Praluent PenAlirocumab | 16 | $14,794 |
| Metoprolol Succinate | 648 | $6,835 |
| Ranolazine ErRanolazine | 77 | $3,749 |
| Rosuvastatin Calcium | 345 | $3,391 |
| Atorvastatin Calcium | 427 | $3,193 |
| Flecainide Acetate | 94 | $2,922 |
| ClopidogrelClopidogrel Bisulfate | 360 | $2,878 |
| Losartan Potassium | 341 | $2,640 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $397 | $459,108528 claims |
| NovartisEntresto | $594 | $282,740246 claims |
| Johnson & JohnsonXarelto | $722 | $150,786158 claims |
| AstraZenecaFarxiga, Brilinta | $605 | $68,43261 claims |
| Boehringer IngelheimJardiance | $401 | $53,27049 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Augusta
- Oladapo FawibeAugusta$79K
- Twinkle SinghAugusta$23K
- Kayla ShahbazianAugusta$21K
- Koosh DesaiAugusta$19K
- Sheng WangAugusta$19K
- Eman KaldasAugusta$18K
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.